These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 25736055

  • 1. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
    Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.
    Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
    [Abstract] [Full Text] [Related]

  • 2. Exosomal miR-141-3p Induces Gemcitabine Resistance in Biliary Tract Cancer Cells.
    Tokuhisa A, Tsunedomi R, Kimura Y, Nakajima M, Nishiyama M, Takahashi H, Ioka T, Kobayashi S, Eguchi H, Nagano H.
    Anticancer Res; 2024 Jul; 44(7):2899-2908. PubMed ID: 38925813
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
    Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M.
    Ann Surg Oncol; 2018 Nov; 25(12):3728-3737. PubMed ID: 30105440
    [Abstract] [Full Text] [Related]

  • 4. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER, Ricker JL, Chen Z, Waes CV.
    Cancer Lett; 2007 Jan 08; 245(1-2):75-80. PubMed ID: 16466850
    [Abstract] [Full Text] [Related]

  • 5. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.
    Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y, Mori M.
    Eur J Cancer; 2013 May 08; 49(7):1725-40. PubMed ID: 23298711
    [Abstract] [Full Text] [Related]

  • 6. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
    Dai CH, Li J, Chen P, Jiang HG, Wu M, Chen YC.
    J Biomed Sci; 2015 Sep 18; 22(1):77. PubMed ID: 26385482
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug 18; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 9. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.
    Cancer Res; 2009 Dec 15; 69(24):9367-75. PubMed ID: 19934314
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
    Ueno G, Iwagami Y, Kobayashi S, Mitsufuji S, Yamada D, Tomimaru Y, Akita H, Asaoka T, Noda T, Gotoh K, Mori M, Doki Y, Eguchi H.
    Ann Surg Oncol; 2022 May 15; 29(5):2899-2909. PubMed ID: 34994902
    [Abstract] [Full Text] [Related]

  • 12. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
    Shen X, Do H, Li Y, Chung WH, Tomasz M, de Winter JP, Xia B, Elledge SJ, Wang W, Li L.
    Mol Cell; 2009 Sep 11; 35(5):716-23. PubMed ID: 19748364
    [Abstract] [Full Text] [Related]

  • 13. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
    Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE.
    Cancer Biol Ther; 2007 May 11; 6(5):654-60. PubMed ID: 17387268
    [Abstract] [Full Text] [Related]

  • 14. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
    Ohashi A, Zdzienicka MZ, Chen J, Couch FJ.
    J Biol Chem; 2005 Apr 15; 280(15):14877-83. PubMed ID: 15671039
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
    Burkitt K, Ljungman M.
    Mol Cancer; 2008 Mar 06; 7():24. PubMed ID: 18325101
    [Abstract] [Full Text] [Related]

  • 17. Effect of midkine on gemcitabine resistance in biliary tract cancer.
    Lu Y, Yan B, Guo H, Qiu L, Sun X, Wang X, Shi Q, Bao Y.
    Int J Mol Med; 2018 Apr 06; 41(4):2003-2011. PubMed ID: 29344648
    [Abstract] [Full Text] [Related]

  • 18. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
    Chen P, Li J, Jiang HG, Lan T, Chen YC.
    Tumour Biol; 2015 May 06; 36(5):3591-9. PubMed ID: 25542235
    [Abstract] [Full Text] [Related]

  • 19. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
    Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.
    Cells; 2019 Sep 03; 8(9):. PubMed ID: 31484399
    [Abstract] [Full Text] [Related]

  • 20. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
    Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ.
    Mutat Res; 2006 Feb 22; 594(1-2):39-48. PubMed ID: 16154163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.